Journal Covers

In Press

• Garcia-Fabiani MB, Haase S, Banerjee K, McClellan B, Zhu Z, Mujeeb A, Li Y, Yu J, Kadiyala P, Taher A, Núñez FJ, Alghamri MS, Comba A, Mendez FM, Nicola Candia AJ, Salazar B, Koschmann C, Nunez FM, Edwards M, Qin T, Sartor MA, Lowenstein PR, Castro MG. “H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas”. bioRxiv. Read more here.

2023

• Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, Woo R, Siddaway R, Burkert M, Stallard S, Qin T, Mullan B, Siada R, Ravindran R, Niculcea M, Dowling AR, Bradin J, Ginn KF, Gener MAH, Dorris K, Vitanza NA, Schmidt SV, Spitzer J, Li J, Filbin MG, Cao X, Castro MG, Lowenstein PR, Mody R, Chinnaiyan A, Desprez PY, McAllister S, Dun MD, Hawkins C, Waszak SM, Venneti S, Koschmann C, Yadav VN. “Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.” Neuro Oncology. Read more here.

• Carney S, Banerjee K, Mujeeb A, Zhu B, Haase S, Varela M, Kadiyala P, Tronrud C, Zhu Z, Mukherji D, Gorla P, Sun Y, Tagett R, Núñez F, Luo M, Luo W, Ljungman M, Liu Y, Xia Z, Schwendeman A, Qin T, Sartor M, Costello J, Cahill D, Lowenstein PR, Castro MG. “Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance.” Clinical Cancer Research. Read more here.

• Haase S, Lowenstein PR, Castro MG. “Sabotaging the Protein Factory to Overcome Glioma Stem Cell Resistance”. Neuro Oncology. Read more here.

• Comba A, Varela ML, Faisal A, Abel C, Argento A, Al-Holou W, Hollon T, Perelman J, Dunn P, Motsch S, Castro MG, Lowenstein PR. “Generation of 3D ex vivo mouse and patient derived glioma explant slice model for integration of confocal time lapse imaging and spatial analysis”. Star Protocols. Read more here

• Varela ML, Comba A, Fasial SM, Argento A, Franson A, Barissi MN, Sachdev S, Castro MG, Lowenstein PR. “Gene Therapy for High Grade Glioma: The Clinical Experience”. Expert Opin Biol Ther. Read more here.

• Wood K, Comba A, Motsch S, Grigera T, Lowenstein PR. “Scale-free correlations and potential criticality in weakly ordered populations of brain cancer cells.” Science Advances. Read more here.

• McClellan B, Haase S, Nunez F, Alghamri M, Dabaja A, Lowenstein PR, Castro MG. “Impact of Epigenetic Reprogramming on Antitumor Immune Responses in Glioma”. Journal of Clinical Investigation. Read more here.

• Faisal SM, Castro MG, Lowenstein PR. Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients. Molecular Therapy. Read more here.

2022

• Umemura Y, Orringer D, Junck L, Varela M, West M, Faisal S, Comba A, Heth J, Sagher O, Leung D, Mammoser A, Hervey-Jumper S, Zamler D, Yadav V, Dunn P, Al-Holou W, Hollon T, Kim M, Wahl D, Camelo-Piragua S, Lieberman A, Venneti S, McKeever P, Lawrence T, Kurokawa R, Sagher K, Altshuler

• D, Zhao L, Muraszko K, Castro MG, Lowenstein PR. “A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma”. The Lancet Oncology. Read more here.

• Haase S, Banerjee K, Mujeeb A, Hartlage C, Nunez F, Nuñez F, Alghamri M, Kadiyala P, Carney S, Barissi M, Taher A, Brumley E, Thompson S, Dreyer J, Alindogan C, Garcia-Fabiani M, Comba A, Venneti S, Ravikumar V, Koschmann C, Carcaboso A, Maria Vinci M, Rao A, Yu J, Lowenstein PR, Castro MG. “H3.3-G34 mutations impair DNA repair and promote GAS/STING-mediated immune responses in pediatric high-grade glioma models”. Journal of Clinical Investigation. Read more here

• Faisal SM, Comba A, Varela ML, Argento AE, Brumley E, Abel C 2nd, Castro MG, Lowenstein PR. “The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications” Front Oncology. Read more here.

• Muthukrishnan S, Kawaguchi R, Nair P, Prasad R, Qin Y, Johnson M, Wang Q, Vanderveer-Harris N, Alvarado A, Condro M, Pham A, Gao F, Gau R, Castro MG, Lowenstein PR, Deb A, Hinman J, Pajonk F, Burns T, Goldman S, Geschwind D, Harley I. Kornblum. “P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells”. Nature Communications. Read more here.

• Cordell E, Alghamri M, Castro MG, Gutmann D. “T lymphocytes as dynamic regulators of glioma pathobiology”. Neuro-Oncology. Read more here.

• Comba A, Faisal SM, Dunn PJ, Argento AE, Hollon TC, Al-Holou WN, Varela ML, Zamler DB, Quass GL, Apostolides PF, Abel C 2nd, Brown CE, Kish PE, Kahana A, Kleer CG, Motsch S, Castro MG, Lowenstein PR. “Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression”. Nature Communications. Read more here.

• Alghamri M, Banerjee K, Mujeeb A, Mauser A, Taher A, Thalla R, McClellan B, Verela M, Stamatovic S, Martinez-Revollar, Andjelkovis A, Gregory JV, Kadiyala P, Calinescu A, Jimenez J, Apfelbaum AA, Lawlor E, Carney S, Comba A, Faisal A, Barissi M, Edwards M, AppelmanH, Sun Y, Gan J, Lahann J, Lowenstein PR, Castro MG. “Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy”. ACS Nano. Read more here.

• McClellan B, Alghamri M, Thalla R, Lowenstein PR, Castro MG. “Murine brain tumor microenvironment immunophenotyping using mass cytometry”. STAR Protoc/Cell Press. Read more here.

2021

• Padma Kadiyala, Stephen V. Carney, Jessica C. Gauss, Maria B. Garcia-Fabiani, Santiago Haase, Mahmoud S. Alghamri, Felipe J. Núñez, Yayuan Liu, Minzhi Yu, Ayman Taher, Fernando M. Nunez , Dan Li, Marta B. Edwards, Celina G. Kleer, Henry Appelman, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro. “Inhibition of 2-Hydroxyglutarate Elicits Metabolic-reprogramming and Mutant IDH1 Glioma Immunity in mice”. Journal of Clinical Investigation. Read more here.

• Garcia-Fabiani MB, Haase S, Comba A, Carney S, McClellan B, Banerjee K, Alghamri MS, Syed F, Kadiyala P, Nunez FJ, Candolfi M, Asad A, Gonzalez N, Aikins ME, Schwendeman A, Moon JJ, Lowenstein PR, Castro MG. “Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment, and Impact Immune-Mediated Therapies”. Frontiers in Oncology. Read more here.

• Shah D, Comba A, Faisal SM, Kadiyala P, Baker GJ, Alghamri MS, Doherty R, Zamler D, Nuñez G, Castro MG, Lowenstein PR. “A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells and is under the control of galectin-1”. Oncoimmunology. Read more here.

• Alghamri M, McClellan B., Avvari R, Thalla R, Kamran N, Zhang L, Faisal S, Ventosa M, Taher A, Núñez FJ, Garcia-Fabiani MB, Carney S., Haase S, Orringer D, Heth J, Patil P, Al-Holou WN, Merajver S, Ulintz PJ, Welch J, Gao C, Liu J, Nunez G, Hambardzumyan D, Lowenstein PR^, Castro MG. “G-CSF Secreted by Epigenetically Reprogrammed Mutant IDH1 Glioma Stem Cells Reverses the Myeloid Cells Mediated Immunosuppressive Tumor Microenvironment”. Science Advances. Read more here.

2020

• Gargini R, Segura-Collar B, Herránz B, García-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P.  “The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas”.  Science Translational Medicine. Read more here.

• Mendez FM, Nunez FJ, Garcia-Fabiani MB, Haase S, Carney S, Gauss JC, Becher OJ, Lowenstein PR, Castro MG.  “Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas:  a neural developmental disease”. Neuro-Oncology. Read more here.

• Padma Kadiyala, Stephen V. Carney, Jessica C. Gauss, Maria B. Garcia-Fabiani, Santiago Haase, Mahmoud S. Alghamri, Felipe J. Núñez, Yayuan Liu, Minzhi Yu, Ayman Taher, Fernando M. Nunez, Dan Li, Marta B.  Edwards, Celina G. Kleer, Henry Appelman, James J. Moon, Anna Schwendeman, Pedro R.  Lowenstein, Maria G. Castro. “Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice”. Journal of Clinical Investigation. Read more here.

• Comba A, Dunn PJ, Argento AE, Kadiyala P, Ventosa M, Patel P, Zamler DB, Núñez FJ, Zhao L, Castro MG, Lowenstein PR. “Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses”. NeuroOncology. Read more here.

• Alghamri MS, Kamran N, Kadiyala P, Lowenstein PR, Castro MG. “Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models”. Methods Enzymol. Read more here.

2019

• Nunez F, Mendez FM, Garcia-Fabiani MB, Pardo J, Edwards M, Lowenstein PR, Castro MG.  “Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin Embedded 3D-Glioma Neurosphere Cultures”.  Journal of Visualized Experiments. Read more here.

• Nunez F, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG. “IDH1R132H acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage response”. Science Translational Medicine. Read more here.

• Kadiyala P, Li D, Nunez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, Lowenstein PR, Castro MG, Schwendeman A. “High density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme”. American Chemical Society Nano (ACS Nano). Read more here.

• Scheetz L, Park KS, Li Q, Lowenstein PR, Castro MG, Schwendeman A, Moon JJ.  “Engineering patient-specific cancer immunotherapies”.  Nature Biomedical Engineering. Read more here.

2018

• Kamran N, Li Y, Sierra M, Alghamri M, Kadiyala P, Appelman HD, Edwards M, Lowenstein PR, Castro MG. “Melanoma induced immunosuppression is mediated by hematopoietic dysregulation”. Oncoimmunology. Read more here.

• Lowenstein PR, Castro MG. “Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients”. Clinical Immunology. Read more here.

• Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein          PR, Castro MG. “Mutant ATRX: uncovering a new therapeutic target for glioma”. Expert Opin Ther    Targets. Read more here.

• Yadav VN, Altshuler D, Kadiyala P, Zamler D, Dunn P, Koschmann C, Castro MG, Lowenstein P.  “Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and anti-angiogenesis”.  Neuro-Oncology. Read more here.

2017

• Calinescu AA, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler D, Doherty R, Srikanth M, Lowenstein PR, Castro MG. “Survival, and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism”. Clinical Cancer Research. Read more here.

• Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG. “Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer”. Cancer Research. Read more here.

• Mendez FM, Nunez F, Zorrilla-Veloz RI, Lowenstein PR, Castro MG. “Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neutrospheres”.  Journal of Visualized Experiments. Read more here.

2016

• Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR.  “CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis:  A genetic knockdown study”. Oncotarget. Read more here.

• Koschmann C, Lowenstein PR, Castro MG. “ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability.” Mol Cell Oncol. Read more here.

• Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG. “ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma”. Science      Translational Medicine. Read more here.

• Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR. “Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells”. OncoImmunology. Read more here.

2015

• Calinescu AA, Núñez FJ, Koschmann C, Kolb BL, Lowenstein PR, Castro MG. “Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma”. Journal of Visualized Experiments. Read more here.

• Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. “Overview of current immunotherapeutic strategies for glioma”. Immunotherapy. Read more here.

• Baker GJ, Castro MG, Lowenstein PR. “Isolation and Flow Cytometric Analysis of Glioma-Infiltrating Peripheral Blood Mononuclear Cells”. Journal of Visualized Experiments. Read more here.

2014

• Mineharu Y, Kamran N, Lowenstein PR, Castro MG. “Blockade of mTOR signaling via Rapamycin Combined with Immunotherapy Augments Anti-Glioma Cytotoxic and Memory T cells’ functions”.  Molecular Cancer Therapeutics. Read more here.

• Lynes J, Wibowo M, Koschmann C, Baker G, Saxena V, Ghulam Muhammad AK, Bondale N, Klein J, Assi H, Lieberman P, Castro MG, Lowenstein PR. “Lentiviral-Induced High-Grade Gliomas in Rats: The Effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H”.  Neurotherapeutics. Read more here.

• Lowenstein PR, Baker GJ, Castro MG. “Cracking the glioma-NK inhibitory code:  toward successful innate immunotherapy”.  OncoImmunology. Read more here.

• Candolfi M, Yagiz K, Wibowo M, Ahlzadeh G, Puntel M, Kamran N, Paran C, Ghiasi H, Lowenstein PR, Castro MG. “Temozolomide does not impair gene therapy-mediated antitumor immunity in syngenic brain tumor models”.  Clinical Cancer Research. Read more here.

• Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu A, Mineharu Y, Carmelo-Piragua S, Orringer D, Bannykh S, Nicholas WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. “Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-independent Vascularization and Resistance to Anti-angiogenic Therapy”. Neoplasia. Read more here.

• Baker G, Chockley P, Yadav V, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. “Natural killer cells eradicate galectin-1 deficient glioma in the absence of adaptive immunity”.  Cancer Research. Read more here.

• Assi H, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele J, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG. “Pre-clinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy”.  Journal of Pharmacology and Experimental Therapeutics. Read more here.

2013

• Puntel M, Muhammad AKMG, Farrokhi C, VanderVeen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick R, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG. “Safety Profile, Efficacy and biodistribution of a bicistronic High-Capacity Adenovirus Vector for a combined immunostimulation and cytotoxic gene therapy as a Prelude to a Phase I Clinical Trial for Glioblastoma”.  Toxicology and Applied Pharmacology. Read more here.

• Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S. “Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials”. Neurologia Medico-Cirurgica Tokyo. Read more here.

• Castro MG, Lowenstein PR. “Neuro-oncology:  The long and winding road –gene therapy for glioma”.  Nature Reviews Neurology. Read more here.

2012

• Zirger JM, Puntel M, Bergeron J, Wibowo M, Moridzadeh R, Bondale N, Barcia C, Kroeger KM, Liu C, Castro MG, Lowenstein PR. “Immune-mediated Loss of Transgene Expression from Virally Transduced Brain Cells Is Irreversible, Mediated by IFNγ, Perforin, and TNFα, and due to the Elimination of Transduced Cells”. Molecular Therapy. Read more here.

• Sanderson NS, Puntel M, Kroeger KM, Bondale NS, Swerdlow M, Iranmanesh N, Yagita H, Ibrahim A, Castro MG, Lowenstein PR. “Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells”.  Proceedings of the National Academy of Sciences, USA. Read more here.

• Mineharu Y, Muhammad AG, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Lui C, Levy E, Lugo C, Kocharian A, Allison J, Curran M, Lowenstein PR, Castro MG. “Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-kB signaling improves the efficacy of immunotherapy in a brain cancer model”.  Neurotherapeutics. Read more here.

• Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AG, Foulad D. Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro, MG. “Plasmacytoid Dendritic Cells in the Tumor Microenvironment:  Immune Targets for Glioma Therapeutics”. Neoplasia. Read more here.

2011

• Mineharu Y, King G, Muhammad AKM, Bannykh S, Kroeger K, Liu C, Lowenstein PR, Castro MG. “Engineering the brain tumor microenvironment enhances the efficacy of dendritic cells’ vaccination: implications for clinical trials design”. Clinical Cancer Research. Read more here.

• Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, Martins G, Lowenstein PR, Castro MG. “B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma”. Neoplasia. Read more here.

2010

• Puntel M, Muhammad AKMG, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG. “A novel bi-cistronic high-capacity gutless adenovirus vector that drives constitutive expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-inducible expression of Flt3L for glioma therapeutics”. Journal of Virology. Read more here.

• Larocque D, Sanderson NRS, Bergeron J, Curtin J, Girton J, Wibowo M, Bondale N, Kroeger KM, Yang J, Lacayo LM, Reyes KC, Farrokh C, Pechnick RN, Castro MG, Lowenstein PR. “Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology”.  Proceedings of the National Academy of Sciences, USA. Read more here.

• Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. “Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics”. Proceedings of the National Academy of Sciences, USA. Read more here.

• Yang J, Sanderson N, Wawrowsky K, Castro MG, Lowenstein PR. “Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell functions in vivo“. Proceedings of the National Academy of Sciences, USA. Read more here.

2009 and earlier

• Ghulam Muhammad AK, Candolfi M, King GD, Foulad D, Yagiz K, Mineharu Y, Kroeger K, Treuer KA, Nichols WS, Sanderson NS, Lowenstein PR, Castro MG. “Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression”. Clinical Cancer Research. Read more here.

• Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz Y, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AKM, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG. “HMGB1 mediates endogenous TLR2 activation and brain tumor regression”. PLoS Medicine. Read more here.

• Candolfi M, Yagiz K, Foulad D, Ahlsadeh GE, Tesarfreund M, Muhammad AKM, Puntel M, Kroeger KM, Liu C, Lee S, Curtin J, King GD, Lerner J, Sato K, Mineharu Y, Xiong W, Lowenstein PR, Castro MG. “Release of HMGB1 in response to pro-apoptotic glioma killing strategies: efficacy and neurotoxicity”. Clinical Cancer Research. Read more here.

• King GD, Muhammad AKM G, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG. “High-capacity adenoviral vector-mediated anti-glioma gene therapy in the presence of systemic anti-adenovirus immunity”. Journal of Virology. Read more here.

• King GD, Kroeger K, Bresee C, Candolfi M, Liu C, Manalo CM, Muhammad A, Pechnick R, Lowenstein PR, Castro MG. “Flt3L in combination with HSV1-TK mediated gene therapy reverses brain tumor-induced behavioral deficits”. Molecular Therapy. Read more here.

• King GD, Muhammad AKM, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG. “Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model”. Neuro-Oncology. Read more here.

• Barcia C, Wawrowsky K, Barrett R, Liu C, Castro MG, Lowenstein PR. “In vivo polarization of IFN-{gamma} at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells”. Journal of Immunology. Read more here.

• Barcia C, Sanderson NS, Barrett RJ, Wawrowsky K, Kroeger KM, Puntel M, Liu C, Castro MG, Lowenstein PR. “T cells’ immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury”. PLoS ONE. Read more here.

• Barcia C, Gomez A, de Pablos V, Fernandez-Villalba E, Liu C, Kroeger KM, Martin J, Barreiro AF, Castro MG, Lowenstein PR, Herrero MT. “CD20, CD3 and CD40L microclusters segregate three-dimensionally in vivo at B Cell-T Cell immunological synapses after viral immunity in primate brain”. Journal of Virology. Read more here.

• Barcia C, Jimenez-Dalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, Larocque D, King GD, Johnson SA, Liu C, Xiong W, Candolfi M, Mondkar S, Ng P, Palmer D, Castro MG, Lowenstein PR. “One year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications”. Molecular Therapy. Read more here.

• Curtin JF, King GD, Barcia C, Liu C, Hubert FX, Guillonneau C, Josien R, Anegon I, Lowenstein PR, Castro MG. “Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain”.  Journal of Immunology. Read more here.

• Barcia C, Thomas CE, Curtin JF, King GD, Wawrowsky K, Candolfi M, Xiong WD, Liu C, Kroeger K, Boyer O, Kupiec-Weglinski J, Klatzmann D, Castro MG, Lowenstein PR. “In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain”. Journal of Experimental Medicine. Read more here.

• Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. “Platelets mediate cytotoxic T lymphocyte-induced liver damage”. Nature Medicine. Read more here.

• Ali S, King G, Curtin J, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassman H, Lowenstein PR, Castro MG. “Combined immuno-stimulation and conditional cytotoxic gene therapy provide long term survival in a large glioma model”.  Cancer Research. Read more here.

• Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, Lowenstein PR. “Stability of lentiviral venter-mediated transgene expression in the brain in the presence of systemic anti-vector immune responses”. Human Gene Therapy. Read more here.

• Hurtado-Lorenzo A, Millan E, Gonzlaez-Nicolini V, Suwelack D, Castro MG, Lowenstein PR. “Differentiation and transcription factor gene therapy in experimental Parkinson’s Disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration”. Molecular Therapy. Read more here.

• Stone D, Xiong W, Williams JC, David A, Lowenstein PR, Castro MG. “Adenovirus expression of IL-1 and NF-kB inhibitors does not inhibit acute adenoviral induced brain inflammation but delays immune system mediated elimination of transgene expression in the presence of pre-existing anti-adenovirus immunity”.  Molecular Therapy. Read more here.

• Grande-Perez A, Sierra S, Castro MG, Domingo E, Lowenstein PR. “Molecular indetermination in the transition to error catastrophe:  systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity”.  Proceedings of the National Academy of Sciences USA. Read more here.

• Zermansky A, Bolognani F, Morrissey G, Castro MG. Lowenstein PR. “Towards global and long-term neurological gene therapy: unexpected transgene dependent, high level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS”. Molecular Therapy. Read more here.

• Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, Lowenstein PR. “Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination”. Nature Biotechnology. Read more here.

• Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. “Pre-existing anti-adenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors”. Human Gene Therapy. Read more here.

• Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. “Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first generation, but not with high-capacity adenovirus vectors: towards realistic long-term neurological gene therapy for chronic diseases”. Proceedings of the National Academy of Sciences USA. Read more here.

• Dewey RA, Morrissey G, Cowsill C, Stone D, Dodd NJF, Bolognani F, Southgate TD, Klatzmann D, Castro MG, Lowenstein PR. “Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials”. Nature Medicine. Read more here.

• Cartmell T, Southgate T, Rees GS, Castro MG, Lowenstein PR, Luheshi GN. “Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain”. The Journal of Neuroscience. Read more here.